Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden

by | Jul 22, 2026 | Clinical Trials | 0 comments

​ Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Tislelizumab; Drug: Tislelizumab Combined With Chemotherapy; Drug: Pembrolizumab

Sponsors: AIO-Studien-gGmbH; BeOne Medicines

Not yet recruiting Conditions: Non-small Cell Lung Cancer Metastatic
Interventions: Drug: Tislelizumab; Drug: Tislelizumab Combined With Chemotherapy; Drug: Pembrolizumab
Sponsors: AIO-Studien-gGmbH; BeOne Medicines
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *